Jump to: navigation, search
Clinical data
Routes of
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass305.413 g/mol

WikiDoc Resources for Dapoxetine


Most recent articles on Dapoxetine

Most cited articles on Dapoxetine

Review articles on Dapoxetine

Articles on Dapoxetine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dapoxetine

Images of Dapoxetine

Photos of Dapoxetine

Podcasts & MP3s on Dapoxetine

Videos on Dapoxetine

Evidence Based Medicine

Cochrane Collaboration on Dapoxetine

Bandolier on Dapoxetine

TRIP on Dapoxetine

Clinical Trials

Ongoing Trials on Dapoxetine at Clinical Trials.gov

Trial results on Dapoxetine

Clinical Trials on Dapoxetine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dapoxetine

NICE Guidance on Dapoxetine


FDA on Dapoxetine

CDC on Dapoxetine


Books on Dapoxetine


Dapoxetine in the news

Be alerted to news on Dapoxetine

News trends on Dapoxetine


Blogs on Dapoxetine


Definitions of Dapoxetine

Patient Resources / Community

Patient resources on Dapoxetine

Discussion groups on Dapoxetine

Patient Handouts on Dapoxetine

Directions to Hospitals Treating Dapoxetine

Risk calculators and risk factors for Dapoxetine

Healthcare Provider Resources

Symptoms of Dapoxetine

Causes & Risk Factors for Dapoxetine

Diagnostic studies for Dapoxetine

Treatment of Dapoxetine

Continuing Medical Education (CME)

CME Programs on Dapoxetine


Dapoxetine en Espanol

Dapoxetine en Francais


Dapoxetine in the Marketplace

Patents on Dapoxetine

Experimental / Informatics

List of terms related to Dapoxetine

Steven C. Campbell, M.D., Ph.D.


Dapoxetine is the International Nonproprietary Name of a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. It is currently in Phase III of the approval process.


If approved, this would make Dapoxetine join the ranks of erectile dysfunction drugs such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®), and some dopamine agonists such as cabergoline (Dostinex®) and pramipexole, as drugs which can be used to improve male sexual health. Misuse of these drugs as aphrodisiacs or sexual enhancers in individuals who do not suffer from sexual health problems is also a possibility and there have been some concerns about doctors being pressured to prescribe such drugs off-label to people who do not actually have a medical need for the drug.

Some research has shown Dapoxetine to have a benefit in the treatment of premature ejaculation.[1]

Approval process

Dapoxetine was created by Eli Lilly and Company and is credited to biochemist David T. Wong. Originally known as LY 210448, it was being developed by Lilly as an antidepressant. Eli Lilly sold the patent to Johnson & Johnson for $65 million dollars and future royalties in December 2003.

Dapoxetine was submitted to the FDA in the form of dapoxetine hydrochloride by the ALZA Corporation and its parent company, Johnson & Johnson for the treatment of premature ejaculation with a New Drug Application (NDA) to the Food and Drug Administration (FDA) on December 28, 2004.

In October of 2005, the FDA issued a "not approvable" letter for dapoxetine.[2]

Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks.


  1. Safarinejad MR (2007). "Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study". doi:10.1038/sj.npp.1301500. PMID 17625501.
  2. http://www.jnj.com/news/jnj_news/20051026_164127.htm

External links